Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Update

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIXGet Rating) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 90,800 shares, a growth of 23.9% from the March 31st total of 73,300 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average trading volume of 56,300 shares, the short-interest ratio is presently 1.6 days.

NASDAQ CPIX opened at $2.39 on Tuesday. The company’s 50 day simple moving average is $2.75 and its two-hundred day simple moving average is $3.31. Cumberland Pharmaceuticals has a 1 year low of $2.19 and a 1 year high of $7.51. The company has a current ratio of 2.37, a quick ratio of 1.93 and a debt-to-equity ratio of 0.35.

CPIX has been the subject of a number of research reports. TheStreet downgraded shares of Cumberland Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Tuesday, February 22nd. StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a research report on Wednesday, April 27th. They set a “hold” rating for the company.

Several large investors have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC bought a new position in shares of Cumberland Pharmaceuticals in the 4th quarter worth $94,000. Marshall Wace LLP bought a new position in shares of Cumberland Pharmaceuticals in the 4th quarter worth $373,000. State Street Corp bought a new position in shares of Cumberland Pharmaceuticals during the 4th quarter valued at $307,000. Citadel Advisors LLC bought a new position in shares of Cumberland Pharmaceuticals during the 3rd quarter valued at $32,000. Finally, Berkshire Asset Management LLC PA grew its holdings in shares of Cumberland Pharmaceuticals by 3.1% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 176,185 shares of the specialty pharmaceutical company’s stock valued at $472,000 after purchasing an additional 5,355 shares during the last quarter. 19.11% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals (Get Rating)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Read More

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.